Singapore National Eye Centre will NEVER ask you to transfer money over a call. If in doubt, call the 24/7 ScamShield helpline at 1799, or visit the ScamShield website at www.scamshield.gov.sg.

Refractive Surgery / SNEC Laser Vision Centre

Synonym(s):

Our Laser Technology

At the SNEC Laser Vision Centre, there is a constant quest to expand the range of refractive errors that can be treated, to improve the predictability and accuracy of the outcomes and to enhance the safety of the surgery. Our specialist team is always at the forefront of innovation, leveraging emerging laser technology to offer customised treatment for patients.

 

WaveLight® EX500 Excimer Laser

This excimer laser by Alcon is a flying spot laser that delivers treatment at 500Hz, with an average treatment time of approximately 1.4 seconds per diopter. It sculpts and treats refractive errors following flap creation by the femtosecond laser.

Faster laser treatment improves the predictability and results of LASIK by reducing the problems of dehydration of the cornea during treatment, flap shrinkage, treatment sensitivity to patient's eye movement and fixation fatigue.

For safety and precision, the laser is coupled with a faster, 1050Hz multi-dimensional eye tracker that tracks horizontal, vertical, rotational and torsional movements of the eye. This excimer laser can also be linked to corneal mapping instruments like the topolyzer and oculyzer, enabling customised mapping of the corneal surface or the global mapping of the eye.

VISUMAX.jpg

 

VISUMAX® Femtosecond Laser

The Visumax® femtosecond laser from Carl Zeiss Meditec is a new generation femtosecond laser platform designed for the creation of corneal flaps during LASIK.

Its repetition rate of 500kHz enables faster flap creation and uses lower energy levels, thereby reducing the amount of thermal energy delivered to the cornea. A specially designed spherically curved contact glass used during the procedure prevents an unnecessarily high rise in intraocular pressure and temporary vision loss during the procedure. The net result is a fast, safe and comfortable LASIK procedure.

VISUMAX.png

 

Wavelight® FS200 Femtosecond Laser System

This efficient Wavelight®FS200 laser system provides a high repetition rate, creating flap with consistent thickness and a special cut pattern to minimize opaque bubble layers. With lower pulse energy, this system creates sharp cutting edges, smooth stromal beds and easy-to-lift flaps.

Wavelight.png

 

HOTLINE: (65) 6322 8891

  EMAIL US

Our Care Team

News

Research Formosa Pharmaceuticals and SERI Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI’s world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD. The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice. Synergy of Innovation and Clinical Excellence A/Prof Yu-Chi Liu, clinician scientist at Singapore National Eye Center and Principal Investigator at SERI, brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions. "Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application," said A/Prof. Yu-Chi Liu. "Our goal is to utilize advanced formulation technologies like APNT to create treatments that are not only more effective but also less burdensome for patients suffering from ocular conditions." Leveraging APNT® Technology Formosa Pharmaceuticals’ APNT® platform specializes in reducing the particle size of active pharmaceutical ingredients (APIs) to stable, uniform nanoparticles. This technology is a hallmark of Formosa's development pipeline, offering a powerful solution for improving the delivery of poorly soluble drugs to the target tissues and organs. "We are honored to work alongside Professor Liu and her distinguished team at SERI," said Erick Co, President & CEO of Formosa Pharmaceuticals. "Initial efforts have confirmed compatibility of APNT and SERI’s research models and prompt us to extend our partnership. SERI’s reputation for excellence in vision research, backed by their comprehensive capabilities and facilities, are unparalleled. Together, we are excited to translate the research findings into better clinical outcomes."
30 Apr 2026 Read Story
Education Singapore National Eye Centre and Singapore Polytechnic collaborate to strengthen optometrists’ role in community eye care The partnership will see both parties co-develop the Clinical Decision-Making in Community Optometry training programme for practicing community optometrists to build on their competencies to deliver quality eye care in the community.
05 Mar 2026 Read Story